Enveda Raises $311 Million to Push Nature-Derived AI Drugs Into Trials

Enveda has raised $311 million in a Series E round that values the biotechnology startup at $2 billion, giving the company fresh capital to move more AI-discovered medicines from the natural world into human testing. The financing, led by Catalio Capital Management with participation from Iconiq and other investors, arrives as Enveda tries to turn plant- and microbe-derived chemistry into a faster drug-discovery engine.

The new round effectively doubles Enveda’s valuation in about a year and underscores growing investor appetite for biotech platforms that pair artificial intelligence with drug development. While AI has not yet produced an FDA-approved medicine, Enveda is now among the companies advancing multiple candidates into clinical trials, including treatments for severe skin disease and for preserving weight-loss results after GLP-1 therapy ends.

For the startup, founded in 2019 by former Recursion Pharmaceuticals employee Viswa Colluru, the latest funding is less about hype than about extending a years-long bet: nature still holds a vast library of potential medicines, and AI can help scientists find them faster than traditional methods.

What Enveda is building

Enveda’s core idea is straightforward but ambitious: instead of inventing every drug molecule from scratch, the company searches the chemistry already present in plants, fungi, microbes, and other natural sources, then uses AI and related computational tools to identify which compounds might become useful medicines.

That approach is designed to accelerate a process that has historically been slow, expensive, and uncertain. Drug discovery often starts with large libraries of synthetic compounds and labor-intensive screening. Enveda argues that nature’s chemistry offers an underused shortcut, because organisms have already evolved highly complex molecules that can interact with biological targets in ways synthetic libraries may miss.

The company says AI helps it sift through that biological diversity more efficiently, prioritizing which natural molecules deserve deeper study and eventual development. In practical terms, the technology is meant to shorten the time between finding a promising compound and learning whether it can become a viable drug.

Why nature is central to the company’s strategy

Nature is central because many of medicine’s most important therapies already came from it. Penicillin, aspirin, paclitaxel, and many other drugs trace their roots to natural compounds or natural inspiration. Enveda is trying to industrialize that legacy with a software-driven search process.

Rather than treating nature as a source of occasional lucky discoveries, the startup views it as a systematic reservoir of chemical possibilities. The company’s pitch is that if scientists can map those molecules and evaluate them computationally, they can surface more candidates with therapeutic promise and less wasted effort.

How big was the funding round?

The round totaled $311 million, and it lifted Enveda’s valuation to $2 billion. That is a notable jump from the level achieved in the company’s prior financing roughly 12 months earlier, when its valuation was about half of the new figure.

The financing was led by Catalio Capital Management, with participation from Iconiq and other backers. The size of the round suggests investors are willing to fund longer, riskier drug-development timelines when the underlying platform appears capable of producing multiple drug candidates rather than a single asset.

Why investors keep backing AI drug discovery

Investors continue to support AI drug discovery because the economics of pharmaceuticals reward even modest improvements in speed and success rates. Bringing a drug to market can take many years and cost enormous sums, and most candidates fail before approval. A platform that improves the odds across several programs can be valuable even if no single candidate succeeds.

That logic has made AI-enabled biotech one of the most closely watched segments of the broader artificial intelligence market. Unlike consumer chatbots or general-purpose software, drug discovery has a clearer path to revenue if the science works, because successful medicines can generate substantial sales and licensing opportunities.

Enveda is also operating in a moment when investors are increasingly differentiating between companies that merely use AI as a marketing label and those embedding it in scientific workflows. The company’s attempt to pair a natural-products strategy with computational screening fits the latter category.

Enveda’s fundraising reflects a broader belief among backers that AI can help biotech companies find better drug candidates earlier in the process, reducing time and waste before compounds ever reach patients.

Which drugs is Enveda testing now?

Enveda is currently testing several compounds in patients, including a drug aimed at severe skin disorders and another intended to help people maintain weight loss after they stop taking GLP-1 medicines.

Those programs show how the startup is trying to diversify its pipeline across different therapeutic areas. Skin diseases can be difficult to treat and often require novel anti-inflammatory or immunology-focused approaches. The post-GLP-1 weight-maintenance idea, meanwhile, targets an emerging commercial need as patients and clinicians look for ways to preserve the benefits of popular obesity drugs after treatment ends.

Advancing multiple candidates into clinical testing matters because it gives the company a chance to prove that its platform can repeatedly generate drugs that are good enough for human trials, not just interesting molecules in a lab notebook.

Why clinical trials matter for AI drug startups

Clinical trials are the first major proof point for AI-driven drug discovery companies. Before that stage, startups can only show that their models identify candidate molecules or predict biological activity. Once a compound enters human testing, investors and partners get a better sense of whether the platform can deliver real medicines rather than theoretical promise.

For Enveda, clinical advancement is especially important because the field still lacks a clear AI-made blockbuster approved by regulators. If the company can keep moving programs forward, it will strengthen the case that AI can contribute materially to pharmaceutical R&D.

Who founded Enveda and what is the company’s background?

Enveda was founded in 2019 by Viswa Colluru, an early employee of Recursion Pharmaceuticals. His background links the startup to a broader wave of computational biotech companies that emerged from the idea that machine learning could transform how medicines are discovered and developed.

Colluru’s experience at Recursion likely helped shape Enveda’s belief that biology, chemistry, and data science can be integrated into a scalable discovery platform. But Enveda’s focus on natural compounds gives it a distinct angle compared with many AI drug companies that rely more heavily on synthetic libraries or structure-based design alone.

The company’s origin story also reflects a larger industry trend: experienced operators from one AI-biotech startup often spin out to pursue adjacent scientific strategies, which helps spread talent, methods, and investor confidence across the sector.

How Enveda fits into the AI biotech boom

Enveda’s funding round arrives amid a broader surge of capital into AI-enabled biotech, a category that continues to attract attention from venture firms, crossover investors, and specialized life-science funds. The reason is simple: if AI can materially improve discovery, development, or trial design, the upside in healthcare could be huge.

But the field is also under pressure to show tangible results. Many companies can demonstrate strong computational capabilities; far fewer can prove that those capabilities translate into drugs that survive the long path from preclinical studies to approval. That gap has made the sector exciting but difficult to evaluate.

Enveda stands out because it is not merely building algorithms in search of a use case. It is already trying to convert those algorithms into human data. That makes its next few years especially important, both for the company and for the wider AI-biotech landscape.

What success could mean for the sector

If Enveda’s programs continue to advance, the startup could validate a model in which AI helps unlock more of nature’s chemical diversity for medicine. That would be meaningful not only for investors, but also for pharmaceutical companies looking for new ways to replenish their pipelines.

Success would also strengthen the argument that AI drug discovery should be measured by clinical outcomes, not just model performance. In an industry where hype can outpace evidence, that distinction matters.

What happens next for Enveda?

The immediate challenge is execution. The company must keep its existing programs moving through the clinic while using the new capital to support additional discovery and development work. Drug development is capital-intensive, and each stage can uncover unexpected scientific or regulatory hurdles.

With a larger balance sheet, Enveda may be better positioned to expand its pipeline, deepen its experiments, and sustain the long timeline required for biotech success. But the real test will come later, when data from its clinical trials begin to show whether its natural-world, AI-first model can produce medicines that are safe and effective enough to matter commercially.

For now, the $311 million round signals that investors are willing to keep financing that experiment. It also suggests that the market sees real potential in a company trying to bring a centuries-old source of medicine discovery into the AI era.

Timeline of Enveda’s rise

That trajectory is unusual even by biotech standards. While many drug startups spend years with little public visibility, Enveda has managed to couple scientific ambition with significant investor momentum. Whether that momentum becomes lasting value will depend on the next phase: data from patients, not just capital from venture firms.

For now, Enveda’s latest raise places it firmly among the most closely watched AI-native biotech companies trying to prove that the natural world still has many medicines left to discover.